Ryvu Therapeutics S.A. (WSE:RVU)

Poland · Delayed Price · Currency is PLN

16.90

-0.18 (-1.05%)

Aug 14, 2026, 5:00 PM CET

Ryvu Therapeutics Earnings Call Transcripts

Fiscal Year 2024

Study Update
RVU120 is being evaluated in four Phase II studies for hematologic malignancies, showing early signs of efficacy and a favorable safety profile, especially in genetically defined AML and MDS cohorts. Enrollment and operational progress are strong, with key data readouts expected in the first half of 2025.

Read full transcript →

Slides